BLS Pharmaceuticals (FRA:PR80) Total Liabilities: €8.20 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:PR80 BLS Pharmaceuticals Ltd FRA:PR80
38 GF Score
Price €0.58
GF Value €0.41
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is BLS Pharmaceuticals Total Liabilities?

BLS Pharmaceuticals FRA:PR80 +6.68% 38 Total Liabilities is €8.20 Mil as of Dec. 2025. GuruFocus rates FRA:PR80 with a GF Score™ of 38/100 and a GF Value™ of €0.41 (Significantly Overvalued). The stock has 8 warning signs investors should review.

BLS Pharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2025 was €8.20 Mil.

BLS Pharmaceuticals's quarterly Total Liabilities declined from Dec. 2024 (€4.87 Mil) to Jun. 2025 (€4.22 Mil) but then increased from Jun. 2025 (€4.22 Mil) to Dec. 2025 (€8.20 Mil).

BLS Pharmaceuticals's annual Total Liabilities increased from Jun. 2023 (€1.66 Mil) to Jun. 2024 (€2.10 Mil) and increased from Jun. 2024 (€2.10 Mil) to Jun. 2025 (€4.22 Mil).

BLS Pharmaceuticals Total Liabilities Historical Data

* Premium members only.

The historical data trend for BLS Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BLS Pharmaceuticals Total Liabilities Chart

BLS Pharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.47 0.65 1.66 2.10 4.22

BLS Pharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.27 2.10 4.87 4.22 8.20
FRA:PR80
38GF Score
BLS Pharmaceuticals Ltd FRA:PR80
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BLS Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

BLS Pharmaceuticals's Total Liabilities for the fiscal year that ended in Jun. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=3.614+(0.606+-0.00099999999999956
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=4.22

Total Liabilities=Total Assets (A: Jun. 2025 )-Total Equity (A: Jun. 2025 )
=11.05-6.831
=4.22

BLS Pharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=5.844+(2.358+-4.4408920985006E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=8.20

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=19.648-11.446
=8.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of €8.20 Mil mean?
BLS Pharmaceuticals (FRA:PR80) has a Total Liabilities of €8.20 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for BLS Pharmaceuticals and its competitors.
Is BLS Pharmaceuticals' Total Liabilities too high?
BLS Pharmaceuticals' current Total Liabilities is €8.20 Mil. Overall, BLS Pharmaceuticals has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BLS Pharmaceuticals' Total Liabilities compare to ?
BLS Pharmaceuticals' Total Liabilities of €8.20 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for BLS Pharmaceuticals and its competitors. BLS Pharmaceuticals's current Total Liabilities is €8.20 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BLS Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, BLS Pharmaceuticals (FRA:PR80) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.41, compared to a current price of €0.58 — trading 41% above its estimated fair value. The current Total Liabilities is €8.20 Mil. BLS Pharmaceuticals' overall GF Score™ is 38/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For BLS Pharmaceuticals (FRA:PR80), the current Total Liabilities is €8.20 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BLS Pharmaceuticals (FRA:PR80) Overvalued in 2026?

Based on GuruFocus' analysis, BLS Pharmaceuticals stock appears to be overvalued. The current stock price of €0.58 is trading 41% above its estimated GF Value™ of €0.41. GuruFocus considers BLS Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for FRA:PR80:

  • Total Liabilities: €8.20 Mil
  • GF Value™: €0.41 vs. price of €0.58 (41% above fair value)
  • GF Score™: 38/100 with 8 warning signs

No single metric tells the full story. See the FRA:PR80 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BLS Pharmaceuticals Business Description

Comparable Companies
Other Exchanges BLS:Australia
Address 50 Clarence Street, Suite 506, Level 5, Sydney, NSW, AUS, 2000
Bioxyne Ltd is an Australian life science and health products company. The company is engaged in the development, manufacture, and distribution of consumer dietary supplements based on the proprietary probiotic strain of Lactobacillus fermentum PCC. Some of its products include Breathe Life Science, Dr Watson, BLS Clinics, Mirai Solution, CanXChange, and others. The company operates in segments, namely, Pharmaceutical manufacture and wholesale supply (business to business), Manufacture and distribution (wholesale, online, and retail), and Wholesale of patented Probiotics.
38GF Score

Get the complete analysis for FRA:PR80

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.58
Price
€0.41
GF Value